A voluntary partial clinical hold has been implemented on a trial in which Starpharma (ASX: SPL, OTCQX: SPHRY) technology is used: AZD0466 Monotherapy or in Combination in Patients with Advanced Haematological Malignancies (NCT04865419).

Further to yesterday’s announcement, Starpharma (ASX: SPL, OTCQX: SPHRY) provides a copy of the investor presentation that was aired during the OTCQX’s Virtual Life Sciences Investor Forum on Thursday, 22 June 2023 at 10:00 am EDT (Friday, 23 June 2023, at 12:00 am AEST).

Starpharma (ASX: SPL, OTCQX: SPHRY) today announces that an investor presentation by Chief Executive Officer, Dr Jackie Fairley, will be broadcast at 10:00 am EDT on Thursday, 22 June 2023 (12:00 am AEST on Friday, 23 June 2023), as part of the OTCQX’s Virtual Life Sciences Investor Forum.

Starpharma today announces the presentation of AZD0466 clinical data by AstraZeneca at the European Hematology Association 2023 Hybrid Congress (EHA Congress), which was held from 8 - 11 June 2023.

Starpharma today announces that it has achieved regulatory approval for its antiviral nasal spray product, VIRALEZE™, in Malaysia. The registration will allow Starpharma and its commercial partners to market and sell the product in Malaysia, a country with a population of over 33 million.